Multicenter, Open Label Study to Evaluate the Predictability of Early Response to Certolizumab Pegol (in Combination With Methotrexate) as Confirmed at Week 52 in Subjects With Moderate-severe Rheumatoid Arthritis (RA).
Phase of Trial: Phase IV
Latest Information Update: 24 Jul 2018
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms CZP-SPEED; SPEED
- Sponsors UCB
- 24 Jul 2018 Results published in the Advances in Therapy
- 10 Jun 2017 Biomarkers information updated
- 10 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.